SPG Prints has confirmed its involvement in developing and delivering Covid-19 rapid test strips in partnership with an international pharmaceutical company.
Due to its experience with biosensors and reputation for creating reliable systems, SPGPrints was invited by an international pharmaceutical company to be involved in the development and delivery of Covid-19 rapid tests. Millions of strips are expected to be produced on both production lines.
‘The usage of biosensors around the world is not new. For over 30 years, biosensors are a quick tool for analyzing diseases, using just a strip and body fluids,’ said Hank Guitjens, commercial manager for label and industrial printing at SPGPrints. ‘A typical application of biosensors in the medical industry is the glucose test strips for diabetes patients.
‘They use these strips to test if their blood sugar levels are deviating from normal. To provide the patient with quick test results, the blood is dripped on a test strip, which is then examined by a diagnostic test device. Within minutes, the patient can see what their exact levels are.’
These biosensor test strips contain an advanced piece of technology. The film used for the test strips must be printed to absorb the body fluid and provide the optimal conditions for this reagent to react.
SPGPrints developed, produced, and delivered a custom-made system for its pharmaceutical partner and offered operator training. This enabled the production company to reach its ideal production levels within weeks after the new system had been delivered.